Skip to main content

Advertisement

Table 1 Pancreatic tumor incidence, multiplicity and metastasis

From: Dimethylaminoparthenolide and gemcitabine: a survival study using a genetically engineered mouse model of pancreatic cancer

Treatment Incidence (%) Incidence, T ≥ 500 mm3(%) Multiplicity Metastasis (%) Liver met (%) Lung met (%)
Placebo 14/14 (100%) 11/14 (78%) 27/14 = 1.9 7/14 (50%) 6/14 (43%) 3/14 (21%)
DMAPT 11/15 (73%) 8/11 (73%) 18/15 = 1.2 5/11 (45%) 2/11 (18%) 5/11 (45%)
Gemcitabine 6/14 (43%)* 2/6 (33%) 6/14 = 0.4* 3/6 (50%) 3/6 (50%) 1/6 (17%)
DMAPT/gemcitabine 9/15 (60%)* 1/9 (11%)* 10/15 = 0.7* 2/9 (22%) 0/9 (0%)*/** 2/9 (22%)
  1. Incidence = number of mice with tumors/total number of mice (n).
  2. Incidence, T ≥ 500 mm3 = number of mice with tumor volume ≥ 500 mm3/number of tumor-bearing mice.
  3. Multiplicity = number of tumors/total number of mice (n).
  4. Metastasis = number of mice with metastases/number of tumor-bearing mice.
  5. Liver Met = number of mice with liver metastases/number of tumor-bearing mice.
  6. Lung Met = number of mice with lung metastases/number of tumor-bearing mice.
  7. *P < 0.05 compared to placebo.
  8. ** P < 0.05 compared to gemcitabine.